ICSI (Intracytoplasmic Sperm Injection) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Intracytoplasmic sperm injection (ICSI) is a specialised in vitro fertilisation (IVF) technique in which a single viable sperm is selected by an embryologist using high-powered inverted microscopy (two hundred to four hundred times magnification), immobilised by touching its tail with a fine glass injection pipette, loaded into the needle, and injected directly into the cytoplasm of a mature metaphase II (MII) oocyte. This micromanipulation technique, first successfully applied to produce a human live birth in 1992 by Palermo et al. at Cornell University, bypasses all natural fertilisation barriers — the zona pellucida, the cumulus-oocyte complex, and the vitellus — enabling fertilisation even when sperm concentration, motility, or morphology is severely impaired. ICSI achieves fertilisation in approximately seventy to eighty-five percent of injected mature oocytes when performed by trained embryologists. ICSI is performed in accredited IVF laboratories under strict quality management conditions. The fertilisation step itself takes ten to twenty minutes in the laboratory and is invisible to the patient — it occurs as part of the day-zero laboratory work following egg retrieval. ICSI does not affect the remainder of the IVF cycle: embryo culture, blastocyst grading, preimplantation genetic testing (PGT), embryo transfer, and the luteal phase support protocol are identical whether fertilisation was achieved by ICSI or conventional IVF insemination.

ICSI has become the dominant fertilisation method in IVF, now used in approximately sixty-five to seventy percent of all fresh IVF cycles globally, though its original indication was specifically severe male factor infertility. Primary indications for ICSI over conventional IVF insemination include: severe oligozoospermia (sperm concentration below five million per millilitre), severe asthenozoospermia (total progressive motility below ten percent), severe teratozoospermia (normal morphology below one percent by Kruger strict criteria), obstructive azoospermia requiring surgical sperm retrieval (TESA, PESA, TESE, micro-TESE) from the epididymis or testis; non-obstructive azoospermia where viable spermatozoa are found on testicular biopsy; elevated antisperm antibodies binding to spermatozoa; total fertilisation failure or very low fertilisation rate (below twenty-five percent) in a previous conventional IVF cycle; use of frozen-thawed semen with significantly reduced post-thaw motility; and when preimplantation genetic testing is performed, as ICSI avoids zona pellucida contamination by extraneous sperm DNA that could interfere with trophectoderm biopsy analysis. ICSI is used at many centres as universal standard for all IVF cycles regardless of sperm quality due to elimination of fertilisation failure risk, moderate additional laboratory cost, and no proven harm in non-male factor couples.

ICSI occurs at the culmination of a standard controlled ovarian stimulation IVF cycle. Eggs are retrieved under transvaginal ultrasound guidance with the patient under intravenous sedation or general anaesthesia approximately thirty-six hours after hCG trigger injection. Retrieved eggs are placed in individual culture drops and assessed for maturity. Only metaphase II (MII) oocytes — those that have completed the first meiotic division and extruded a first polar body — are suitable for ICSI. In the ICSI procedure, the embryologist places each MII oocyte on a holding pipette (gentle suction) on the inverted microscope stage at a controlled temperature. A single motile spermatozoon is selected from the prepared sperm sample, immobilised by lightly touching its midpiece to break the plasma membrane and prevent tail movement (membrane disruption is believed to improve fertilisation rates), and aspirated into a fine glass microinjection needle of approximately seven micrometres internal diameter. The needle is advanced through the zona pellucida and into the oocyte cytoplasm under microscopic visualisation; successful intracytoplasmic delivery is confirmed by injecting a minimal volume (approximately five picolitres) before carefully withdrawing the needle. Fertilisation is confirmed by observing two pronuclei (2PN) at sixteen to eighteen hours post-injection — one from the egg and one from the injected sperm. Resulting zygotes are cultured to cleavage stage (day three) or blastocyst stage (day five) before transfer or cryopreservation.

ICSI provides the only reliable route to fertilisation and biological parenthood for men with severe oligozoospermia, azoospermia treated by surgical sperm retrieval, or other serious sperm defects that prevent natural fertilisation. Without ICSI, these men would have no option for genetically related children except donor sperm. Fertilisation rates of seventy to eighty-five percent per injected mature oocyte are achieved by experienced ICSI embryologists — rates that exceed conventional IVF in unselected populations, and are superior to conventional insemination in male factor cases by thirty to forty percentage points. Clinical pregnancy rates per ICSI embryo transfer are equivalent to conventional IVF for comparable egg quality and recipient age, and live birth rates per ICSI cycle average thirty to fifty percent in women under thirty-five in high-quality centres (European IVF Monitoring Consortium, EIM data 2022), declining progressively with maternal age. ICSI also enables use of spermatozoa obtained by minimally invasive microsurgical extraction (micro-TESE) from men with non-obstructive azoospermia — conditions including Klinefelter syndrome (47,XXY) and Sertoli-cell-only syndrome — in whom ejaculated spermatozoa are absent but focal spermatogenesis may persist in the seminiferous tubules.

ICSI shares all risks of the standard IVF process. Ovarian hyperstimulation syndrome (OHSS) — the most serious ovarian complication — occurs in one to five percent of stimulated cycles and may cause abdominal pain, bloating, nausea, ascites, pleural effusion, thrombosis, and rarely renal failure. Freeze-all embryo strategies using gonadotropin-releasing hormone agonist trigger instead of hCG eliminate severe OHSS in high-risk (PCOS, high AFC) patients. The egg retrieval procedure carries a small risk of bleeding, infection, and inadvertent visceral puncture (each less than one percent). Multiple pregnancy — with its attendant prematurity, low birthweight, and maternal risks — is the primary preventable complication, now substantially reduced by single embryo transfer (SET) policies at most evidence-based centres. ICSI-specific concerns involve the theoretical risk of bypassing natural sperm selection, potentially allowing sperm with DNA fragmentation or genetic abnormalities to fertilise the egg. Large retrospective meta-analyses show a modest increase in chromosomal abnormalities (approximately one percent higher than conventional IVF) and rare imprinting disorders (Angelman syndrome, Beckwith-Wiedemann syndrome) in ICSI children — though these absolute risks remain very small. Whether these risks relate to ICSI technique or to inherent genetic abnormalities in severely infertile men is debated. Preimplantation genetic testing (PGT-A for aneuploidy, PGT-M for monogenic disorders) can screen embryos before transfer.

Recovery after ICSI is identical to recovery from a standard IVF egg retrieval cycle. Following egg retrieval under sedation, patients rest in the recovery area for one to two hours before discharge home accompanied by a responsible adult. Mild to moderate pelvic cramping, bloating, and vaginal spotting are expected for twenty-four to forty-eight hours after retrieval, managed with paracetamol and rest. Strenuous exercise and sexual intercourse are avoided until after the pregnancy test result. Progesterone supplementation — by vaginal pessary (Cyclogest 400 mg twice daily), vaginal gel (Crinone 8%), intramuscular injection, or oral tablets — begins on the day of egg retrieval or the day after, continuing until twelve weeks of pregnancy if conception is confirmed. Fertilisation results (number of 2PN embryos) are communicated by the embryology team on the morning after retrieval. Embryo development and transfer day are confirmed over the next three to five days of culture. If fresh embryo transfer is planned, it occurs on day three (cleavage) or day five (blastocyst). A serum beta-hCG pregnancy test is performed ten to fourteen days after egg retrieval. If the result is positive, ultrasound at six to seven weeks confirms intrauterine implantation and foetal heartbeat.